Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and -independent pathways

Microbiology and Immunology

Volumn 55, Issue 11, 2011, Pages 774-782

  Nakashima, Kenji ^a   Takeuchi, Kenji ^a,b   Chihara, Kazuyasu ^a,b   Hotta, Hak ^c   Sada, Kiyonao ^a,b  

^a Faculty of Medical Sciences   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 aminoimidazole 4 carboxamide 1 D ribofuranoside (AICAR); Adenosine monophosphate activated protein kinase (AMPK); Diabetes; Metformin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA DEXTRO RIBOFURANOSIDE; COMPOUND C; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME REPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PROTEIN FUNCTION; TREATMENT RESPONSE; VIRUS REPLICATION;

CELL LINE; CULTURE MEDIA; GLUCOSE; HEPACIVIRUS; HEPATOCYTES; HUMANS; METFORMIN; PROTEIN KINASES; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 81155123213     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2011.00382.x     Document Type: Article

References (44)

1. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., Houghton M. (2007) The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 6: 991-1000.
2. Inoue M., Kurahashi N., Iwasaki M., Tanaka Y., Mizokami M., Noda M., Tsugane S. (2009) Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). Cancer Causes Control 20: 741-50.
3. Bressler B.L., Guindi M., Tomlinson G., Heathcote J. (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639-44.
4. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., Salmeron J., Diago M., Fernandez-Rodriguez C.M., Corpas R., Cruz M., Grande L., Vazquez L., Munoz-De-Rueda P., Lopez-Serrano P., Gila A., Gutierrez M.L., Perez C., Ruiz-Extremera A., Suarez E., Castillo J. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-41.
5. Carling D., Clarke P.R., Zammit V.A., Hardie D.G. (1989) Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 186: 129-36.
6. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. (1995) 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells Eur J Biochem 229: 558-65.
7. Dyck J.R., Gao G., Widmer J., Stapleton D., Fernandez C.S., Kemp B.E., Witters L.A. (1996) Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. J Biol Chem 271: 17798-803.
8. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., Alessi D.R., Hardie D.G. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2: 28
9. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., Schlattner U., Wallimann T., Carlson M., Carling D. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004-8.
10. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., Frenguelli B.G., Hardie D.G. (2005) Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2: 9-19.
11. Woods A., Dickerson K., Heath R., Hong S.P., Momcilovic M., Johnstone S.R., Carlson M., Carling D. (2005) Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2: 21-33.
12. Hawley S.A., Davison M., Woods A., Davies S.P., Beri R.K., Carling D., Hardie D.G. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-87.
13. Munday M.R., Campbell D.G., Carling D., Hardie D.G. (1988) Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur J Biochem 175: 331-8.
14. Clarke P.R., Hardie D.G. (1990) Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J 9: 2439-46.
15. Horman S., Browne G., Krause U., Patel J., Vertommen D., Bertrand L., Lavoinne A., Hue L., Proud C., Rider M. (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-23.
16. Lochhead P.A., Salt I.P., Walker K.S., Hardie D.G., Sutherland C. (2000) 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49: 896-903.
17. Horman S., Vertommen D., Heath R., Neumann D., Mouton V., Woods A., Schlattner U., Wallimann T., Carling D., Hue L., Rider M.H. (2006) Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281: 5335-40.
18. Kasai D., Adachi T., Deng L., Nagano-Fujii M., Sada K., Ikeda M., Kato N., Ide Y.H., Shoji I., Hotta H. (2009) HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol 50: 883-94.
19. Blight K.J., McKeating J.A., Rice C.M. (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-14.
20. Bungyoku Y., Shoji I., Makine T., Adachi T., Hayashida K., Nagano-Fujii M., Ide Y.H., Deng L., Hotta H. (2009) Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 90: 1681-91.
21. Inubushi S., Nagano-Fujii M., Kitayama K., Tanaka M., An C., Yokozaki H., Yamamura H., Nuriya H., Kohara M., Sada K., Hotta H. (2008) Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein tyrosine kinase Syk. J Gen Virol 89: 1231-42.
22. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., Rice C.M. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-6.
23. Shukla U., Hatani T., Nakashima K., Ogi K., Sada K. (2009) Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT. J Biol Chem 284: 33719-28.
24. Sada K., Miah S.M., Maeno K., Kyo S., Qu X., Yamamura H. (2002) Regulation of FcepsilonRI-mediated degranulation by an adaptor protein 3BP2 in rat basophilic leukemia RBL-2H3 cells. Blood 100: 2138-44.
25. Qu X., Sada K., Kyo S., Maeno K., Miah S.M., Yamamura H. (2004) Negative regulation of FcepsilonRI-mediated mast cell activation by a ubiquitin-protein ligase Cbl-b. Blood 103: 1779-86.
26. Mankouri J., Tedbury P.R., Gretton S., Hughes M.E., Griffin S.D., Dallas M.L., Green K.A., Hardie D.G., Peers C., Harris M. (2010) Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci U S A 107: 11549-54.
27. Thomas C.B., Meade J.C., Holmes E.W. (1981) Aminoimidazole carboxamide ribonucleoside toxicity: a model for study of pyrimidine starvation. J Cell Physiol 107: 335-44.
28. Sabina R.L., Holmes E.W., Becker M.A. (1984) The enzymatic synthesis of 5-amino-4-imidazolecarboxamide riboside triphosphate (ZTP). Science 223: 1193-5.
29. Owen M.R., Doran E., Halestrap A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3): 607-14.
30. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-8.
31. Foretz M., Hebrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., Andreelli F., Viollet B. (2010) Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Clin Invest 120: 2355-69.
32. Kawaguchi T., Yoshida T., Harada M., Hisamoto T., Nagao Y., Ide T., Taniguchi E., Kumemura H., Hanada S., Maeyama M., Baba S., Koga H., Kumashiro R., Ueno T., Ogata H., Yoshimura A., Sata M. (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165: 1499-508.
33. Kawaguchi T., Ide T., Taniguchi E., Hirano E., Itou M., Sumie S., Nagao Y., Yanagimoto C., Hanada S., Koga H., Sata M. (2007) Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102: 570-6.
34. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-95.
35. Saha A.K., Avilucea P.R., Ye J.M., Assifi M.M., Kraegen E.W., Ruderman N.B. (2004) Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 314: 580-5.
36. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-74.
37. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., Bartenschlager R., Wakita T., Hijikata M., Shimotohno K. (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nature Cell Biology 9: 1089-97.
38. Leu G.Z., Lin T.Y., Hsu J.T. (2004) Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 318: 275-80.
39. Kapadia S.B., Chisari F.V. (2005) Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102: 2561-6.
40. Ye J., Wang C., Sumpter R. Jr., Brown M.S., Goldstein J.L., Gale M. Jr. (2003) Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100: 15865-70.
41. Pietschmann T., Lohmann V., Rutter G., Kurpanek K., Bartenschlager R. (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 75: 1252-64.
42. Zhu Q., Guo J.T., Seeger C. (2003) Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol 77: 9204-10.
43. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750-8.
44. Romero-Gomez M., Diago M., Andrade R.J., Calleja J.L., Salmeron J., Fernandez-Rodriguez C.M., Sola R., Garcia-Samaniego J., Herrerias J.M., De la Mata M., Moreno-Otero R., Nunez O., Olveira A., Duran S., Planas R. (2009) Treatment of insulin resistance with metformin in naive genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 50: 1702-8.